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Purpose: Sarcopenia, the loss of muscle mass combined with the loss of muscle function,
has become a public health issue. There is an urgent need for interventions. The study aimed
to determine the effect of high-intensity resistance training (HI-RT), a time- and cost-efficient
training modality, on sarcopenia in osteosarcopenic (OS) older men.
Methods: Forty-three community-dwelling men aged ≥72 years from Northern Bavaria,
Germany, with OS were randomly assigned to either an active HI-RT group (HI-RT) or an
inactive control group (CG). Both received dietary protein (up to 1.5 g/kg/day in HI-RT and
1.2 g/kg/day in CG) and Vitamin-D (up to 800 IE/d) supplements. The HI-RT was applied as
a consistently supervised single-set training on resistance exercise machines using intensify-
ing strategies, with two training sessions/week, structured into three phases (ranging from 8
to 12 weeks) totaling 28 weeks. The primary study endpoint was the Sarcopenia Z-score;
secondary endpoints were changes in the underlying physiological parameters, skeletal
muscle mass index (SMI), handgrip-strength and gait velocity.
Results: The results show a significant effect of the exercise intervention on the sarcopenia
Z-score in the HI-RT (p<0.001) and a significant worsening of it in the CG (p=0.012) in the
intention-to-treat analysis, as well as a significant intergroup change (p<0.001). Analysis
upon the underlying parameters showed a significant increase of skeletal muscle mass index
(SMI) in the HI-RT group (p<0.001) and a significant intergroup difference of SMI
(p<0.001) and handgrip strength (p<0.001). There were no adverse effects related to dietary
supplementation or training.
Conclusion: The results clearly confirm the favorable effects of HI-RT on sarcopenia. We
conclude that HI-RT is a feasible, highly efficient and safe training modality for combating
sarcopenia, also in the elderly.
Keywords: HI-RT, high-intensity resistance training, osteosarcopenia, sarcopenia, SMI,
community-dwelling, older people
Introduction
Sarcopenia – the degeneration of muscle mass combined with loss of muscle function
due to aging1 has become a public health matter.2 The multiple adverse health outcomes
associated with low muscle mass (fractures and falls,3–7 insulin resistance and the risk of
prediabetes,8,9 cardiovascular diseases,10 cognitive impairment,11 depression12 and
others13), the impact of sarcopenia on the individual’s life (loss of independence,14
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reduced quality of life,12,15,16 earlier necessary admission to
nursing homes14,17) and the resulting socioeconomic
burden18–20 have made the necessity for interventions clear.
Many studies have already proven the positive effects of
resistance training (RT) combined with a protein-rich diet on
sarcopenia.21–26 A standardized treatment approach that can
be applied to a wide range of sarcopenic patients and includes
a validated training protocol has yet to be defined. The training
should be time-efficient, considering reasons for abstaining
from recommended exercise doses have been time restriction
and little enthusiasm27,28 and cost-efficient in the face of the
high and growing prevalence of sarcopenia29 and the resulting
financial burden for stakeholders.18,19,30–32 A training modal-
ity meeting these criteria is high-intensity resistance training
(HI-RT), a single-set resistance training at an intensity of load
at 70–85% of the one-repetition maximum (1RM).33 To have
a maximum effect on muscle strength and mass and also
parameters like bone density34,35 and hormonal levels,36 rela-
tive intensity of 70% RM and up is needed, which falls in the
range of HI-RT.
A protocol using a modern high-intensity method has not
been applied to the often fragile30 cohort of sarcopenic
patients. It is time to challenge the presumptions of HI-RT
being too demanding and risky for the elderly and make use
of this efficient training modality for sarcopenic patients.
This study is the first to assess HI-RT as a favorable therapy
option for osteosarcopenic community-dwelling men, with
this publication focusing on sarcopenia, while the aspect of
osteopenia will be dealt with in another publication.
Our central hypothesis was that HI-RT combined with
supplemental protein has a significant effect on Sarcopenia,
ie, the Sarcopenia Z-score, compared to the control group
(CG), which only received protein supplementation.
Our secondary hypothesis was that skeletal muscle
mass index (SMI), as an underlying physiologic parameter
of the Sarcopenia Z-score, significantly increases in the
HI-RT group compared to the CG.
Methods
Trial Design
The Franconian Osteopenia and Sarcopenia Trial (FrOST) is
an 18-month randomized controlled exercise study with
a balanced parallel two-group design. The research focusses
on a cohort of community-dwelling men 72 years and older
with morphological sarcopenia and osteopenia. FrOST pre-
dominately pursues two main aims. (1) To determine the
effect of HI-RT on bone parameters related to osteoporosis;
(2) to evaluate the impact of HI-RT on muscular parameters
related to Sarcopenia. The present publication reports
changes in sarcopenia criteria from within the first 6 months
of the intervention (June–December 2018). The Institute of
Medical Physics (IMP), University of Erlangen-Nürnberg
(FAU), Germany, planned, initiated and realized the project,
which was approved by the University Ethics Committee of
the FAU (Ethikantrag 67_15b and 4464b). The study com-
plies with the Helsinki Declaration “Ethical Principles for
Medical Research Involving Human Subjects.” After receiv-
ing detailed information, all study participants gave their
written informed consent. The project was registered under
ClinicalTrials.gov: NCT03453463.
Participants
Participant recruitment of the FrOST was a multi-stage pro-
cess. We based FrOST on the Franconian Sarcopenic Obesity
(FranSO) study,37 an epidemiologic study with 965 commu-
nity-dwelling men 70 years+, conducted in 2016. Precisely 24
months later, in January/February 2018, participants from the
lowest quartile for SMI (n=242) were invited for a 2-year
follow-up (2-year FU) assessment. Out of them, 177 men 72
+ were willing to participate and remained after applying the
following inclusion criteria: a) Community-dwelling status; b)
no amputations of limbs or cardiac pacemaker implants during
the last 2 years; c) no (new) implementation of glucocorticoid
therapy >7.5 mg/d during the previous 2 years; d) no cognitive
impairment that could confound the assessments38 and e) no
alcohol abuse of more than 60 g/d ethanol. These 177 remain-
ing men then got reevaluated (2-year FU): only participants
with an SMI <7.50 kg/m2 (n=103) as determined by direct-
segmental, multi-frequency Bio-Impedance-Analysis (DSM-
BIA) were further invited for body composition and
bone mineral density analysis using Dual-Energy X-ray
Absorptiometry (DXA). Subjects were finally included in
FrOSTwhen
a) SMI, as assessed by DXA, was below 7.26 kg/m2
(≤−2 standard deviations (SD) T-Score, ie, sarcopenia1,39),
b) bone mineral density at the region of interest (ROI), ie,
either the lumbar spine or the proximal femur (total hip or
femoral neck) was ≤-1 SD T-Score (ie, osteopenia40),
c) there was no secondary osteoporosis or history of
hip fracture and subjects would be able to visit our lab or
the gym. Finally, 43 men were eligible and willing to
participate in the study. Correspondingly, these 43 subjects
were randomly assigned either to a HI-RT (n=21) or an
inactive CG (n=22). Figure 1 shows the participants’ flow
through the study.
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Randomization Procedures
Stratified for SMI (3 strata), the 43 study participants
were randomly and equally assigned to two study arms,
a) HI-RT (n=21) or b) CG (n=22). By drawing lots,
participants allocated themselves to the study group.
Lots were placed in opaque plastic shells (“kinder
egg,” Ferrero, Italy) and drawn from a bowl. Neither
participants nor researchers knew the allocation
beforehand. Subsequently, the primary investigator
Wolfgang Kemmler (WK) enrolled participants and
instructed them in detail about their status, including
corresponding dos and don´ts.
Blinding
We conducted a blinded approach that focused on outcome
assessors and test assistants only. Outcome assessors were
Figure 1 Participants’ flow through the study.
Abbreviations: DSM-BIA, direct-segmental multi-frequency bioimpedance analysis; DXA, dual-energy X-ray absorptiometry; HI-RT, high-intensity resistance training; CG,
control group; FU, follow-up; ITT, intention to treat.
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unaware of the participant’s group status (HI-RT or CG) and
were not allowed to ask correspondingly.
Study Procedure and Intervention
Subjects have been intensively informed about dos and don’ts
by the principal study investigator (WK). Maintaining and not
changing physical activity and exercise outside the study
intervention as well as maintaining dietary habits has been
requested of them. Furthermore, all participants have been
asked to restrain from intense physical activity and exercise
48 h pre-assessment.
Exercise Protocol
The consistently supervised resistance exercise training
started in June 2018 and has been performed in a well-
equipped gym (Kieser-Training, Erlangen, Germany),
which is centrally located and can be easily reached via
public transportation.
Participants of the HI-RT group have been provided
with training logs, which prescribe exercises, number of
sets (first phase only), number of repetitions (reps), move-
ment velocity and the required exercise intensity (non-
repetition maximum (nRM), repetition maximum (RM)
or work to failure (MF))41 in the given training phase.
The following example is intended to help the reader
better understand the concept of intensity in resistance
training and how modification of repetition maximum
and load regulate intensity.
An athlete who can lift 100 kg in the bench press in the
correct form once has a 1RM of 100 kg for that specific
exercise, thus lifting 75–80 kg would fall into the range of
75–80%RM, defined as the intensity of load.42 Work to fail-
ure refers to the intensity of effort and means respective
athlete can lift x repetitions until muscle failure (MF), ie,
the “set endpoint when trainees complete the final repetition
possible whereby if the next repetition was attempted they
would definitely achieve MF” as defined by Giessing et al.43
In practice, the work to failure approach is usually achieved
with a self-determined repetition maximum (sdRM), mean-
ing the “set endpoint when the trainee determines they could
not complete the next repetition if it were attempted (ie, they
predict MF on the following repetition) as Steele et al41 have
extended the four definitions by Giessing et al.43
We did not prescribe a precise number of reps or
a given load as deduced by 1RM assessments or 1RM
calculated by xRM-tests (eg, Ref. 44). Instead, we pre-
scribed the range of reps and the corresponding level of
effort (nRM, RM) to regulate exercise intensity.
Consequently, the participants had to choose a weight
for themselves with which they could perform an exercise
x-y times (= prescribed range of reps) in order to reach the
predefined intensity of effort (= prescribed level of effort)
During the first 28 weeks of the intervention, the resistance
training (RT) was structured into three phases with 2 training
sessions/week. (Either on Monday or/and Wednesday or/and
Friday morning.) During phase 1, we started with 4 weeks of
briefing and familiarization, and a further 8 weeks of condi-
tioning. Strong emphasis was put on bringing the importance
of the proper relationship between repetitions and correspond-
ing load across to the patients under the premise of the pre-
scribed repetition maximum.41 Per session, 12 out of 14
exercises (latissimus front pulleys, rowing, back extension,
inverse fly, bench press, shoulder press, lateral raises, butterfly
with extended arms, crunches, leg press, leg extension, leg
curls, leg adduction and abduction) were conducted over the
full range of motion on resistance-devices (MedX, Ocala, FL,
USA). The protocol prescribed 1–2 sets of 8–15 reps, time
under tension of 2s concentric, 1s isometric and 2s eccentric
(2s-1s-2s) per rep and a non-repetition maximum (nRM: max-
imum effort minus 1–3 reps).41 Breaks between sets or exer-
ciseswere consistently 90−120 s.Applying these criteria to the
example earlier, the bodybuilder would first have to determine
which weight he can lift on the bench press 15 times with
correct form before MF and then deduct 1–3 reps, thus lifting
this determined weight for 12–14 reps in order to reach the
non-repetition maximum.41
During phase 2, the single-set approach, characteristic
for HI-RT, was implemented. Up from this phase, we
applied 8-week phases, each consisting of 2 linearly period-
ized four 4-week phases, with each fourth week as
a recovery week with low exercise intensity. Fourteen to
fifteen exercises out of a pool of 18 (additionally to the
above-listed exercises, calf raises, hip extension, pullovers,
lateral crunches) were applied. Apart from the 10 core
exercises consistently used, weekly sessions slightly differed
for the exercises prescribed. Apart from the recovery weeks
with no prescription of nRM, the protocol prescribed 7–18
reps/set, selecting a load that ensured maximum effort (RM)
−1 rep (up to 10 reps) to −2 reps (more than 10 reps). Of
importance, we did not prescribe a target repetition (eg, 7
reps). Instead, we specified a repetition sector (7–10 reps)
that should be realized by the participants keeping in mind
the level of effort (nRM, RM). Breaks between the exercises
were consistently 90 s. We generated periodization by
decreasing the number of reps from 15–18 reps/set/session
to 7–10 reps/set/session during the 3-week cycle of linear
Lichtenberg et al Dovepress
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periodization. We placed strong emphasis during phase 2 on
movement velocity that varied between 4s-1s-4s to 1s-1s-2s
per rep. However, we did still not focus on an explosive
movement during the concentric phase during phase 2.
Coming back to the exemplary bodybuilder, during phase
2, he would start with a weight in the bench press, which he
would be able to perform 20 reps with and then deduct 2
reps from it to determine the nRM. Over 3 weeks, he would
decrease the number of repetitions down to 7–10 reps still
ensuring to reach the nRM by choosing correspondingly
higher loads.
Using a comparable training schedule described for phase
2; however, with a slightly lower range of repetitions (12–15
decreasing to 6–8 reps), the repetition maximum approach41
characteristic for HI-RT was introduced during phase 3. We
carefully increased the number of (core) exercises that should
be executed almost to muscular failure (here: defined as
1RM41) from four during week 1 to eight in week 7 (week
8 was a recovery week). Figure 2 visualizes the exercise
protocol.
Protein Supplementation
Protein supplementation has been based on 4-day dietary
protocols (see below). We have intended a total protein intake
of 1.5 g/kg body mass/d in the HI-RT and a corresponding
intake of 1.2 g/kg body mass/d25 in the CG. Participants with
a dietary protein intake <1.5 g/kg/d (HI-RT) or <1.2 g/kg/d
(CG) have been provided with protein supplements. The pro-
tein powder used in FrOST (Active PRO80, inkospor, Roth,
Germany) consists of whey protein with a chemical score of
156. One hundred grams contain 80 g of protein (10.4 g of
Leucine), 5 g of carbohydrates and 1.8 g of fat resulting in
a calorific value of 362 kcal/100 g protein powder.
Furthermore, 300 mg of calcium has been enclosed with
a 25 g/portion of the protein powder. Participants have been
requested to ingest the prescribed dose accurately on a daily
base and to split doses higher than 30 g/d. We have suggested
to mix the protein powder with low-fat milk when applicable
(or possible) in order to increase the participants’ dietary
calcium intake. Compliance with prescribed protein powder
intake has been queried regularly during the exercise sessions.
Vit-D/Calcium Supplementation
Based on blood concentrations of 25 OHVitamin-D 3 (25-OH
D3), participants with levels below 30 ng/mL (n=37) have
been asked to supplement 10.000 IE/week (2x2500 IE/d, twice
a week; MYVITAMINS, Manchester, UK). Participants
between 30 and 40 ng/mL (n=4) have been requested to take
5.000 IE/week (2x2500 IE/d, once a week).
We have intended to realize a calcium intake of about
1000 mg/d in all participants.45 Based on a dietary calcium
questionnaire (Rheumaleague Suisse), we calculated the
amount of daily dietary calcium intake. After also consid-
ering the calcium provided by the protein powder, we
prescribed the additionally required daily calcium to be
ingested by calcium capsules (Sankt Bernhard, Bad
Dietzenbach, Germany). Each capsule contains 625 mg
of calcium-carbonate with 250 mg of pure calcium.
Study Outcomes
Primary Outcome
Changes in Sarcopenia Z-score applying the European
Working Group of Sarcopenia in Older People
(EWGSOP I) approach1 from baseline to six-month FU.
Figure 2 Exercise protocol.
Abbreviations: reps, repetitions; con, concentric; iso, isometric; ecc, eccentric; nRM, non-repetition maximum; RM, one-repetition maximum.
Dovepress Lichtenberg et al
Clinical Interventions in Aging 2019:14 submit your manuscript | www.dovepress.com
DovePress
2177
 
Cl
in
ica
l I
nt
er
ve
nt
io
ns
 in
 A
gi
ng
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
87
.1
63
.6
2.
15
0 
on
 0
2-
Ap
r-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Secondary Outcomes
Changes in Sarcopenia criteria constituting the Sarcopenia
Z-score from baseline to six-month FU, ie,
● Changes in SMI
● Changes in habitual gait velocity
● Changes in handgrip strength
Changes to Trial Outcomes After Trial
Commencement
No changes to trial outcomes were conducted after trial
commencement.
Assessments
Baseline and FU assessments were performed using the iden-
tical calibrated devices, in precisely the same setting and at the
same time of the day (±90 mins). However, research assistants
who guided and supervised the tests were not consistently
identical between baseline and 6-month FU.
The Sarcopenia Z-score, according to the EWGSOP-I
approach, included SMI, gait velocity and handgrip strength.
Cut-off values applied were 0.8 m/s for gait velocity and
30 kg for handgrip strength. However, divergent from the
cut-off value for skeletal muscle mass index (SMI) suggested
by the EWGSOP-I for BIA assessments,46–48 we applied the
“Weissenfels Score” (7.177 kg/m2),b (T-Score-based
approach of SMI (ASMM/height2) based on 2 SD below
the mean value of a young reference cohort of 1189 healthy
Caucasian men 18–35 years old.) specifically designed for
this northern Bavarian cohort of CD men 70 years+.49 Based
on the cut-offs and individual data, we calculated the
Sarcopenia Z-score:
Z-Score = ((30 - individual handgrip strength)/SD
handgrip strength) + ((0.8 - individual gait velocity)/SD
gait velocity) + ((7.177 - individual SMI)/SD SMI).
Height was measured using a stadiometer (Holtain,
Crymych Dyfed., Great Britain), body mass and composi-
tion were determined via direct-segmental multi-frequency
bioimpedance analysis (DSM-BIA; InBody 770, Seoul,
Korea) and by DXA (QDR 4500a, Discovery-upgrade,
Hologic Inc., Bedford, USA). In both cases, we applied
standard protocols suggested by the manufacturer. Since
we opt to focus on BIA assessment of muscle mass during
the 6-month FU assessment, we would like to report
methods of DXA evaluation of bone mineral density and
body composition in a future publication.
Soft lean body mass was defined as bone and fat-free
body mass. Body fat (%) refers to the amount of fat in the
whole body. Comparable to the calculation of the BMI (ie,
body mass/height2; kg/m2) and following the approach
suggested by Baumgartner et al,50 skeletal muscle mass
index (SMI) was calculated as fat-free mass of the upper
and lower extremities (=appendicular skeletal muscle
mass) divided by squared body height (kg/m2). In order
to standardize the BIA assessment, we consistently used
the same BIA test protocol, which includes minor physical
activity for 8 hrs and 15 mins of rest in a supine position
immediately before the BIA assessment. Furthermore, all
participants were provided with written specifications
about dos and don’ts, including essential nutritional gui-
dance 24 before testing.
A standardized assessment of habitual gait speed51 was
performed using the 10 m protocol recommended for
research.52 Participants started walking in an upright position
3 m before the first photosensor (HL 2–31, TagHeuer, La
Chaux-de-Fonds, Suisse) and stopped 2 m after the second
photosensor. Tests were performed wearing regular shoes
without any specific walking aids. Standardized instructions
to the participants were consistently “walk at a speed just as if
you were walking along the street to go to the shops.”
Handgrip strength was tested three times each for the
dominant and the non-dominant hand using a calibrated
Jamar handgrip dynamometer (Sammons Preston Inc.,
Bollington, USA). Handgrip width was adjusted individu-
ally to participant hand size. Tests were performed while
standing upright, arms down by the side53 with 30 s rest
between the trials. The standardized instruction to the
participants was consistently “squeeze as strongly as pos-
sible.” We included the highest result of the three trials for
the dominant hand in the analysis.
General characteristics (eg, family and educational sta-
tus, professional career), medication, diseases and lifestyle
(including physical activity and exercise54), falls, injurious
falls, fractures and self-rated degree of independence were
determined using a standardized questionnaire completed
by the participants while visiting our lab. Before the tests,
we asked participants to list their medications and diseases
in order to generate completeness and accuracy of the
questionnaire. This summary was checked by the principal
investigator (WK) in cooperation with the participants
before the tests were conducted. During this interaction,
the degree of independence and autonomy, family status,
social network and use of ambulatory nursing services was
inquired more specifically. The 6-month FU questionnaire
predominately focused on changes in confounding vari-
ables concerning lifestyle, including physical activity and
Lichtenberg et al Dovepress
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exercise, diseases, medication and dietary intake. Further,
we asked for falls and self-rated degree of independence.
Sample Size
Sample size analysis of FrOST was based on quantitative
computed tomography (QCT) of the lumbar spine.
However, since this or other bone parameters were not
determined at 6-month FU, we would like to report the
statistical power of our sample size (HI-RT: n=21 vs CG:
n=22) with the focus on the Sarcopenia Z-score. Applying
a t-test based sample size calculation to the effect (exercise
vs CG) on Sarcopenia Z-score (0.46±0.51) reported by
a comparable trial with older men,37 the sample size of
21 participants/group corresponds to a 86% power (1-β) at
a type-I-error of alpha=0.05.
Statistical Analysis
The intention to treat (ITT) analysis included all participants
who were randomly assigned to the two study arms (HI-RT
vs CG) regardless of their compliance or whether they were
lost to FU. R statistics software (R Development Core Team
Vienna, Austria) was used in combination with multiple
imputation by Amelia II.55 The full data set was used for
multiple imputations, with imputation being repeated 100
times. Overimputation diagnostic plots provided by Amelia
II confirmed that the multiple imputation worked well in all
cases. Based on a statistically and graphically checked
normal distribution, the primary and secondary outcomes
that are addressed here were analyzed by dependent t-tests
for within-group (intra-group) changes. Pairwise t-test com-
parisons (HI-RT vs CG) with pooled SD were applied in
order to identify group differences. Mean values (MV),
standard deviations (SD) and 95% confidence intervals
(95% CI) were used to describe the data. Additionally, we
applied a per-protocol analysis (PPA) for the primary study
endpoint that included only participants with complete data
sets. To identify differences between the groups, we used
repeated-measures ANOVA in the PPA. All tests were two-
tailed; significance was accepted at p <0.05. We further
calculate Standardized Mean Difference (SMD) according
to Cohen (d`;56) to analyze effect sizes.
Results
One participant of the CG and two participants of the HI-
RT group got lost to FU. Concerning the latter group, one
man withdrew immediately after randomization (did not
agree with the group assignment), another participant was
unable to visit the 6-month FU due to therapy of prostate
cancer. One man of the CG was unable to visit the
6-month FU due to influenza infection. Attendance to the
HI-RT sessions was high.
In summary, subjects participated in 95±4% of the 52
sessions. The average exercise time/session after the con-
ditioning period was 50 ± 9 mins. Apart from periods of
muscle pain and delayed onset of muscular soreness
(DOMS), no further exercise-induced complaints or unin-
tended side effects were reported. Table 1 gives baseline
characteristics. Apart from body height, no significant
differences between the groups were observed.
Tables 2–4 report changes from baseline to 6-month
FU assessment: Tables 2 and 3 in primary and secondary
endpoints and Table 4 in potentially confounding para-
meters. Asterisks indicate the significance levels of
intragroup changes. Differences in absolute changes
between the groups are reported using mean difference
and 95% confidence intervals (95% CI). Finally, in the
right row of the table, exact p-values are listed for baseline
differences and differences in absolute change in the given
parameter between the CG and HI-RT. Additional listings
in the text complete this data; absolute p-values for
intragroup changes, SMD for group differences in absolute
Table 1 Baseline Characteristics of the Participants of the CG
and HI-RT Group
Variable CG
(n=22)
HI-RT
(n=21)
p
Age [years] 79.2 ± 4.7 77.8 ± 3.6 0.262
Body height [cm] 169.2 ± 5.5 172.8 ± 5.2 0.039
Body mass [kg] a 70.2 ± 7.1 74.7 ± 10.1 0.113
Soft lean body mass [kg] a 46.9 ± 3.4 48.4 ± 3.3 0.164
Total body fat rate [%] 28.6 ± 5.8 30.5 ± 6.8 0.330
Number of diseases [n] b 2.14 ± 0.92 2.00 ± 1.11 0.656
Hip or knee arthrosis [n] 2 2 0.959
Chronic low back pain [n] 4 3 0.731
Physical activity [Index] c 4.15 ± 1.53 4.45 ± 1.32 0.490
Exercisers [n] 13 11 0.654
Training volume [min/week] 59 ± 56 46 ± 52 0.780
25 OHD baseline [ng/mL] 21.6 ± 8.4 17.5 ± 7.0 0.126
Energy intake [kcal/d] d 2291 ± 590 2155 ± 416 0.407
Protein intake [g/d]d 89.3 ± 25.9 81.6 ± 19.9 0.299
Independence grade [Index]e 1.68 ± 0.82 1.80 ± 0.80 0.791
Smokers [n] 4 3 0.959
Notes: aAs determined by DSM-BIA (InBody 770, Seoul, Korea). bUsing the ICD-10-
based disease cluster of Schäfer et al.57 cScale from (1) very low to (7) very high.54 dAs
determined by a 4-day dietary record. eRating scale from 1 (no help from others to
conduct my daily life at all) to 7 (unable to conduct most challenges of daily life).
Abbreviations: DSM-BIA, direct-segmental multi-frequency bioimpedance analy-
sis; HI-RT, high-intensity resistance training; CG, control group.
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change and percentage changes from baseline to follow-up
are mentioned where applicable and meaningful.
Changes in the primary study endpoint are in Table 2.
Based on widely identical baseline data, the Sarcopenia
Z-score significantly (p<0.001) improved in the HI-RT and
significantly worsened in the CG (p=0.012). Differences
between the groups concerning Sarcopenia-Z-score changes
are significant (p<0.001; SMD 1.89). The additionally per-
formed per-protocol analysis using repeated measures
ANOVA confirms this result with a slightly lower effect size
(p<0.001; SMD 1.77).
Addressing the underlying criteria of the Sarcopenia
Z-score according to EWGSOP-I,1 ie, SMI, habitual gait
velocity and handgrip strength, we observed significant
Table 2 Baseline Data and Changes in the Sarcopenia Z-Score in the GC and HI-RT and Corresponding Between-Group Differences
CG MV±SD HI-RT MV
±SD
Difference MV
(95% CI)
p-Value
Sarcopenia Z-score [Index]
Baseline −0.11 ± 1.18 −0.09 ± 1.94 – 0.981
Six-month
follow-up
0.43 ± 0.74* −1.01 ± 0.78*** 1.44 (0.95 to 1.92) <0.001
Notes: *P<0.05; ***P<0.001.
Abbreviations: HI-RT, high-intensity resistance training; CG, control group; MV, mean value; SD, standard deviation; CI, confidence interval.
Table 3 Baseline Data and Changes in the Sarcopenia Criteria in the Control Group (CG) and High-Intensity Resistance Training
Group (HI-RT) and Corresponding Between-Group Differences
CG MV ± SD HI-RT MV ± SD Difference MV (95% CI) p-Value
Skeletal Muscle Mass Index (SMI) [kg/m2]
Baseline 7.10 ± 0.30 7.07 ± 0.33 – 0.681
Changes −0.03 ± 0.21 0.30 ± 0.22*** 0.33 (0.19 to 0.46) <0.001
Habitual gait velocity [m/s]
Baseline 1.26 ± 0.15 1.25 ± 0.17 – 0.803
Changes −0.004 ± 0.051 0.016 ± 0.055 0.020 (−0.01 to 0.06) 0.091
Handgrip strength [kg]
Baseline 30.0 ± 4.3 30.7 ± 5.1 – 0.675
Changes −2.04 ± 2.13*** 0.15 ± 2.26 2.19 (0.78 to 3.06) <0.001
Notes: ***P<0.001.
Abbreviations: HI-RT, high-intensity resistance training; CG, control group; MV, mean value; SD, standard deviation; CI, confidence interval.
Table 4 Changes in Potentially Confounding Parameters in the CG and HI-RT and Corresponding Between-Group Differences
CG MV±SD HI-RT MV±SD Difference MV (95% CI) p-Value
Dietary energy uptake [kcal]
Changes 7.8 ± 135 13±166 5 (−93 to 104) 0.971
Dietary Protein uptake [g/d]
Changes −2.1 ± 12.9 3.5 ± 16.4 5.6 (−4.0 to 15.3) 0.251
Physical activity [Index]a
Changes 0.20 ± 0.88 0.22 ± 0.91 0.02 (−0.58 to 0.63) 0.941
Notes: aBased on a scale from (1) very low to (7) very high; see Table 1.
Abbreviations: HI-RT, high-intensity resistance training; CG, control group; MV, mean value; SD, standard deviation; CI, confidence interval.
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increases for SMI in the HI-RT (+4.2%, p<0.001) and slight
decreases in the CG (−0.4%, p=0.548). The difference
between the groups was significant (p<0.001, SMD: 1.53)
(Table 3). Habitual gait velocity did not change in the CG
(−0.3%, p=0.639) and slightly increased in the HI-RT (+1.3%,
p=0.061). The difference between the groups was not signifi-
cant (p=0.091, SMD: 0.38) (Table3). Handgrip strength main-
tained in the HI-RT (+0.5%, p=0.89) and significantly
decreased in CG (−6.8%, p<0.001). Differences between the
groups were significant (p<0.001, SMD: 1.00)
Table 4 gives changes in parameters with a potential
impact on our results. There were no relevant changes in
diet or lifestyle and participants did not report changes in
habitual exercise habits. Apart from the participants that were
lost to follow-up (prostate cancer), no participant listed rele-
vant changes in medication, diseases, musculoskeletal inju-
ries or cardiometabolic events. Extended periods (≥2 weeks)
of diseases or inactivity were also not recorded.
Discussion
The presented results clearly confirm our primary hypoth-
esis – HI-RT combined with supplemental protein (HI-
RT&P) had a significantly favorable effect on Sarcopenia,
ie, the decrease of the Sarcopenia Z-score, compared to the
CG, which only received protein supplement.
This result indicates that without exercise stimuli, sar-
copenia naturally progresses and worsens and that the
amount of supplemented protein in the CG (1.2 g/kg/d25)
alone was ineffective in maintaining muscle mass and
function. We had at least expected maintenance of muscle
strength and muscle mass because of the benefits of pro-
tein supplementation reported on in several
publications25,26 and the positive results of the FranSO
study by Kemmler et al,37 which formed the basis of
FrOST. FranSO indicated a sole effect of protein supple-
mentation, even when no exercise was performed. Having
said that, it has to be taken into account that in respective
trial, an amount above the recommended protein intake
(1.7 versus 1.2–1.6 g/kg/day25,58) had been prescribed and
this amount of 1.7 g/kg/day was furthermore a much
higher amount of consumed protein by the non-exercise
CG than in FrOST, in which the non-exercise CG only
received 1.2 kg/d. Looking at the positive effect of mere
supplementation in the FranSO non-exercise CG as
opposed to the lack of effect of supplementation in our
trial's non-exercise CG raises the question, whether what is
considered an adequate protein intake for the elderly, is
actually sufficient. We disregard differences in the formula
of the protein powders as a possible reason for this dis-
crepancy because the critical variable Leucine26,59–62 was
comparably high in both trials. (Levels of Leucine, 9 vs
10.4 g/100 g). Thus, it can be asked whether a protein
intake of 1,7-up g/kg/day should be reevaluated with the
dosage being the second variable to be considered for
explaining this observation. A meta-analysis by Morton
et al contradicts additional effects of higher protein con-
sumption than 1,6 g/kg/day,63 and discussions on general
effectivity of protein supplementation continue, but there
are strong arguments speaking for an increased intake,
too. 58,63–68 Nevertheless, the possible adverse effects of
higher protein intake on kidney and colon health cannot be
neglected.58 Thus, an optimized balance between not too
low, but safe enough has to be aimed for. Further investi-
gations are needed to find the maximum dose for certain,
specified target groups. However, even with a lower dose
of protein than used in the FranSO trial, our training
intervention led to a high increase in muscle mass in the
HI-RT group, which proves our second hypothesis right –
muscle mass significantly increased in the HI-RT&P
group, compared to baseline value and the CG.
The change from baseline to FU showed a gain in skeletal
body mass of 4.2% at a significance level of <0.001, and
although we had aimed at such positive results, we did not
anticipate this increase because of the blunted hypertrophic
potential of skeletal muscles at older age.69 Looking at the
hypertrophic effect found in our HI-RT group, we speculate
that the higher training stimuli outperformed the blunted ana-
bolic system of this older, sarcopenic cohort. This assumption
is in linewith a recent umbrella reviewbyBeckwée et al stating
that more significant improvements in outcomes correlate with
higher training intensities.22 The data by Giessing et al23 about
higher muscular performance and mass gain from HI-RT in
comparison to traditional high-volume resistance training (HV-
RT, ie, high number of repetitions and/or sets and/or
frequency23,70,71 at low-moderate intensity33) support our find-
ings as well. Not only exist those advantages of HI-RT but also
are there several disadvantages of HV-RT, eg, the longer time
of recovery72 along with an increased risk of overtraining and
a greater inflammatory response72 which itself is considered
one factor in the genesis of sarcopenia.73,74 Additionally, high
levels of heart rate and systolic blood pressure have been
observed in HV-RT sets,75 another factor that plays a role for
sarcopenic patients, which often demonstrate cardiovascular
comorbidities.76 To the best of our knowledge, our study is the
first to evaluate the effects of HI-RT in combination with
dietary supplementation on sarcopenic community-dwelling
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men of such advanced age. Altogether, it was difficult to make
valid comparisons to other studies due to heterogeneity in
intervention duration, the modality of resistance training, diet-
ary supplements, cohort size, gender, age, definitions applied
and missing training protocol. WB-EMS-training
interventions37,77 with comparable cohorts have also found
significant effects on sarcopenia parameters, including the
Sarcopenia Z-score. However, the 4.24% increase in SMI
was unique to FrOST and outstanding, FranSO achieved an
increase in SMI of 2.54%. As listed in the introduction, many
adverse health outcomes are correlated with a decrease in
muscle mass.3–13 On the contrary, positive health outcomes
come along with growth of muscle mass. The gain of such is
associated with a higher basal metabolic rate78,79 helping com-
bat sarcopenic obesity80, and an increase in capillary density81
and Vo2 peak82, both improving cardiovascular economy.
Furthermore, in recent years, Sarcolipin (SLN) has gained
attention, and contrary to previous findings, it has been found
to be the leading player in thermogenesis.83Of importance, this
micropeptide is mainly expressed in striated muscle.84 SLN
ultimately increases ATP hydrolysis and consequently leads to
heat production the muscle,85 which demands a high level of
energy. Thus, next to playing a vital role in non-shivering
thermogenesis86, it is a determinant of basal metabolic rate.87
This is yet another example of the functions of muscle tissue
emphasizing on the importance of maintaining and regaining
muscle mass.
Apart from muscle mass as one underlying parameter of
the Z-score, we also found a significant intergroup effect for
handgrip strength, which was maintained in HI-RT, but sig-
nificantly decreased in GC. Handgrip strength is easy and
inexpensive to measure in clinical practice88,89 and thus has
been put into focus for early detection89 and diagnosis of
sarcopenia.90 More importantly, low handgrip strength has
been discovered as a predictive marker for future falls91–93
and has also been related to incident cardiovascular
disease88,94 and cardiovascular mortality88 conditions, which
are amongst the top 20 causes for disability-adjusted life years
(DALYs).95 It can be said that it is crucial to maintain muscle
strength to combat frailty and mortality, and our intervention
sufficed to ensure this. Addressing habitual gait velocity as the
last parameter underlying the Z-score, we did not find
a significant outcome. Even though gait speed is considered
to be a measurand for lower extremity muscle function,96
reciprocally, lower extremity muscle function is not the only
factor impacting gait speed. Age-related motor neuron
degradation,97 range of motion in joints of the lower
extremities98 and non-muscular factors (eg, cognitive
status99,100 and depression101) impact gait speed, while muscle
mass plays aminor role.97 Thus, we do not find it alarming that
gait velocity did not increase significantly.
Apart from the strengths of our study, we want to
address some limitations in order to help the reader assess
our results and the generalizability of our findings: First of
all, the time from baseline to FU was 28 weeks with only 8
weeks of a purebred HI-RT (ie, RM41 in phase 3). During
phases 1 and 2, our participants exercised mostly within the
suggested range (training intensity between 75% and 80%
RM102) for novice to moderately trained individuals, as our
subjects can be classified. However, work to momentary
muscle failure (MF) being the second criterion that defines
HI-RT23,33 was not introduced during the first three training
periods. In our case, trainees chose an intensity of load at
75–85% of their 1RM, which within a defined repetition
range, ensured an intensity of effort (sdRM) that almost led
to MF. Hence, not all of our protocol followed a high-
intensity approach per se. However, we found it absolutely
necessary to build good exercise habits first and then pre-
pare the subjects for the demanding phase 3. By applying
this strategy, we have successfully managed to avoid inju-
ries. Furthermore, by getting the group slowly used to this
unfamiliar training method, we have avoided drop-outs and
established a high level of compliance. Although we only
applied the strict high-intensity approach in phase 3 for 8
weeks, the outcome was still extraordinarily high. We raise
the question of whether we can expect a further significant
increase in outcomes from the remaining intervention, now
continuously applying the classical HI-RT approach until
the end of FrOST? Answers will be given by a later pub-
lication, which will be evaluating the endpoint outcomes
along with focusing on the outcomes regarding osteopenia.
Secondly, the sample size of this trial might be considered
as rather small (n=21 and n=22). Indeed, the project has been
powered on BMD-changes at the LS as determined by QCT.
However, a sample size calculation that addresses the
Sarcopenia Z-Score provided power at 86% to detect
a p<0.05 difference using validated assumptions. Thus, we
consider the sample size and corresponding statistical power
as appropriate in addressing our research topic.
Lastly, we used BIA for measuring the SMI, and there
have been the arguments posing an overestimation of SMI by
BIA103 and consequently suggesting a higher cut-off value of
7.9 kg/m2 for males than we did (7.177 kg/m2). We consider
the BIA vs DXA discussion irrelevant for the quality of our
study for several reasons: 1) In previous studies, Kemmler
et al have determined a high interclass correlation between
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their DSM-BIA (InBody770) and DXA scanner (Hologic
4500a) for ASMM49,104 and Ling et al have found an “excel-
lent agreement” of BIA and DXA.105 2) We used BIA for
both, baseline and FU, so a possible general overestimation
of the SMI would have had no statistical impact. 3) As
explained in the methods section of this publication, we
used a specifically designed T-score49 for our cohort, ensur-
ing the inclusion of only eligible subjects.
Overall, we are delighted with the outcomes of FrOST.
We followed a high-quality methodological and statistical
approach, showed multiple significant improvements and
provided a precise exercise protocol as asked for by
reviews, eg, “Exercise interventions in healthy older adults
with sarcopenia: A systematic review and meta-analysis”
by Vlietstra21 to ensure comparability and generalizability.
Conclusion
In conclusion, we summarize that HI-RT in combination with
protein supplementation is a favorable intervention strategy to
reduce the risks, progression and burden of sarcopenia. The
high changes in muscle mass and sarcopenia Z-score can be
achieved in an inexpensive, time-efficient and safe manner.
The high compliance and lack of injuries in our cohort proved
that HI-RT is indeed feasible for the elderly. The present study,
along with data from the FranSO-study indicates that there is
some evidence, which proposes that protein doses ≥1.7 g/kg/
daymight be required formaintenance ofmusclemasswithout
resistance training. Furthermore, studieswith a similar exercise
protocol changing different variables (eg, trial duration, exer-
cise frequency) should be conductedwithmore cohorts to have
a higher comparable amount of HI-RT trials.
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